Non-small cell lung cancer metastatic Trials in Lille, France
Conditions / Non-small cell lung cancer metastatic / Lille, France
Non-small cell lung cancer metastatic has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT02117167 | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | COMPLETED | PHASE2 |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03469960 | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | COMPLETED | PHASE3 |
| NCT04233021 | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation | COMPLETED | PHASE2 |
| NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | NOT_YET_RECRUITING | — |
| NCT03977194 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07563205 | Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer | RECRUITING | — |
| NCT04111705 | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT03774732 | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |